Impel NeuroPharma rises after launch of migraine treatment

IPI Legacy Liquidation Co

28/09/2021 16:40

** Drug developer's shares  IMPL.O  up ~11% at $14.75
    ** Co says Trudhesa, its migraine treatment approved by the
U.S. FDA earlier this month, is now available for prescription
 urn:newsml:reuters.com:*:nL4N2Q52SO
    ** Trudhesa is now available through Trudhesa Direct, a
process that provides prescribing, savings, and home delivery
facilitated by co's digital pharmacy partners, Carepoint
Pharmacy and Phil Inc- IMPL
    ** Co says that for each prescription, patients will receive
four single-use products of the treatment  urn:newsml:reuters.com:*:nGNX7mzBWq
    ** Shares had fallen 1.6% YTD

 (Reporting by Oishee Majumdar in Bengaluru)
 ((oishee.majumdar@thomsonreuters.com;))